menu
    • menu

    Looking for excipients offered by The Dow Chemical Company? Find information on The Dow Chemical Company's regulatory filings (DMFs), cGMP inspections, pricing availability, etc. on PharmaCompass.

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dow Pharma & Medical is a global leader in research, manufacturing and innovation of functional excipients, API’s and silicon-based technologies for medical device fabrication and pharmaceutical processing. It has the material science expertise and global market and regulatory experience to help customers deliver innovative solutions for healthcare challenges of today and tomorrow; bringing new products to market faster and ...
    Dow Pharma & Medical is a global leader in research, manufacturing and innovation of functional excipients, API’s and silicon-based technologies for medical device fabrication and pharmaceutical processing. It has the material science expertise and global market and regulatory experience to help customers deliver innovative solutions for healthcare challenges of today and tomorrow; bringing new products to market faster and extending product life-cycles.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    The Dow Chemical CompanyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2030 Dow Center, Midland, MI 48674
    Telephone
    Telephone
    +1 800 447 4369
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pharma.dupont.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dow-chemical
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 4791

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024

    FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024

    The year 2024 was marked by some landmark drug approvals in the areas of schizophrenia, metabolic dysfunction-associated steatohepatitis (MASH), chronic obstructive pulmonary disease (COPD) and Alzheimer’s disease. The incoming Trump administration, monkeypox outbreak and drug price negotiations in the US also created big news. Here is PharmaCompass’ compilation of the top 10 news from Phispers of 2024. I. BMS’ US$ 14 bn Karuna bet pays off with landmark FDA approval for schizophrenia med Cobenfy The US Food and Drug Administration’s groundbreaking approval of Bristol Myers Squibb’s Cobenfy to treat schizophrenia has made it to our number one spot. BMS had acquired Cobenfy through its US$ 14 billion purchase of Karuna Therapeutics, announced in December 2023. Cobenfy is the first-ever antipsychotic that targets cholinergic receptors. Cobenfy’s new approach has experts excited. Its peak sales are expected to come in at US$ 7.5 billion a year. While BMS’ Karuna buyout paid off, AbbVie’s US$ 8.7 billion acquisition of Cerevel Therapeutics was dampened when their lead candidate and schizophrenia drug emraclidine failed to meet phase 2 endpoints in two pivotal trials. II. 2024’s biggest deal, US$ 16.5 bn Catalent buyout by Novo’s parent, cleared after intense scrutiny  On number two spot is Novo Nordisk Foundation’s acquistion of Catalent via its investment arm Novo Holdings for US$ 16.5 billion, announced in February 2024. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. Easily the biggest biopharma acquisition of last year, the deal  faced criticism from lawmakers and consumer groups for its potential anti-competitive effects, particularly in the glucagon-like peptide-1 (GLP-1) drug market. Its main competitor Eli Lilly called for scrutiny by competition regulators. However, in December, both the EU regulator and the US Federal Trade Commission gave it the greenlight. III. Madrigal’s Rezdiffra becomes first FDA-approved drug for liver disease MASH For quite some time, the drug development field for the liver condition MASH had been a graveyard for failed programs. In 2024, the field celebrated a hurrah moment when Madrigal’s oral drug Rezdiffra became the first treatment in the US for adults with this common fatty liver disease. The approval has opened a multi-billion dollar opportunity for Madrigal with the American Liver Foundation CEO Lorraine Stiehl calling it a “game-changing” moment. IV. COPD patients get two new treatments — Verona’s Ohtuvayre and Sanofi-Regeneron’s Dupixent The COPD landscape saw remarkable advances in 2024. FDA approved Verona Pharma’s Ohtuvayre, which brings the first new mechanism of action in over two decades for the treatment of COPD. This dual-action, inhaled medication serves as both a bronchodilator and an anti-inflammatory agent, offering a comprehensive approach to symptom management. Adding to this progress, Sanofi and Regeneron’s Dupixent achieved a historic milestone by becoming the first biologic approved for treating COPD. Over 390 million people are living with COPD worldwide. V. Novartis inks 20 deals in 2024, promises over US$ 25 billion in biobucks, lays bets on radiopharmas Novartis has been investing in early-stage science, buying out companies in the sub-US$ 5 billion range. The Swiss drugmaker Novartis inked over 20 deals in 2024, paying over US$ 5.5 billion upfront and promising over US$ 25 billion in biobucks. The company has particularly focused on radiopharmaceuticals and molecular glue degraders. It acquired Mariana Oncology to strengthen its radioligand therapy (RLT) pipeline, and also inked RLT deals with PeptiDream and Ratio Therapeutics. VI. Despite political pressure, FDA rejects first MDMA-assisted therapy to treat PTSD; Lykos faces expanded probe In August, FDA declined to approve an MDMA-assisted therapy from Lykos Therapeutics to treat post-traumatic stress disorder (PTSD). In the lead-up to the FDA decision, 80 members of Congress from both sides of the aisle had urged US President Joe Biden and the FDA to consider further studies on the therapy. Not satisfied with just declining Lykos’ MDMA-assisted therapy for PTSD, FDA had expanded its investigation into the clinical trials that tested it. Lykos CEO Amy Emerson stepped down after reducing its workforce by 75 percent. Additionally, its founder Rick Doblin exited its board. VII. Alzheimer’s gets two new treatments as FDA approves Lilly’s Kisunla, Alpha Cognition’s Zunveyl FDA finally approved Eli Lilly’s Alzheimer’s drug Kisunla in July, after delaying action on it in March. This approval, along with that of Biogen and Eisai’s Leqembi in 2023, mark successes in treating the mind-wasting disease after three decades of failed efforts. FDA also approved Alpha Cognition’s Zunveyl to treat mild-to-moderate Alzheimer’s disease. Zunveyl is a prodrug of Alzheimer’s medication galantamine, and is to be taken orally twice a day. Alpha said Zunveyl is designed to address the tolerability issues with galantamine. VIII. IRA price talks conclude; Stelara, Enbrel, Eliquis to bring 51.4% of Medicare savings After filing futile lawsuits questioning the constitutional validity of the Medicare drug price negotiations under the Inflation Reduction Act (IRA), all drug companies came to the bargaining table. In August, the Biden-Harris Administration announced it had reached agreements for lower prices for all 10 drugs selected for negotiations under the IRA. The new prices come into effect from January 1, 2026. A Brookings Institution report said that just three drugs will account for over half of the expected US$ 6 billion savings in 2026. J&J’s Stelara (US$ 1.4 billion), Amgen’s Enbrel (US$ 1.1 billion), and BMS’ Eliquis (US$ 856 million) are expected to account for US$ 3.28 billion or 51.4 percent of Medicare savings. IX. Trump’s picks for new administration send shockwaves across markets, stocks of vaccine makers tumble  Donald Trump’s picks for his new administration not only created big news, but also impacted the stock markets. His selection of Robert F. Kennedy Jr., an anti-vaccine activist, to lead the Department of Health and Human Services (HHS), sent shares of several vaccine manufacturers plummeting. In the US, stocks of Pfizer, Moderna, and Novavax dipped. In Europe, stocks of BioNTech, GSK, and Bavarian Nordic tumbled. Trump has nominated Mehmet Oz, a celebrity TV host, to run the Centers for Medicare and Medicaid Services (CMS), which oversees health insurance. X. New mpox outbreak in Africa sparks global response; FDA approves Emergent’s vaccine to treat mpox In August, a new mpox virus clade put Africa in the throes of an mpox outbreak. The WHO declared it a public health emergency of international concern. Emergent BioSolutions said it will donate 50,000 doses of its smallpox vaccine ACAM2000. Multiple countries responded with donations of Bavarian Nordic’s Jynneos, the only widely-approved mpox vaccine at the time. In early September, the FDA approved Emergent’s ACAM2000 as the second mpox vaccine.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1108

    https://www.pharmacompass.com/radio-compass-blog/fda-s-landmark-approvals-of-bms-schizo-med-madrigal-s-mash-drug-us-16-5-bn-catalent-buyout-make-it-to-top-10-news-of-2024

    #Phispers by PHARMACOMPASS
    02 Jan 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    WHO warns of falsified cough syrup ingredients seized in Pakistan
    WHO warns of falsified cough syrup ingredients seized in Pakistan

    16 Apr 2024

    // REUTERS

    https://www.reuters.com/world/asia-pacific/who-warns-falsified-cough-syrup-ingredients-seized-pakistan-2024-04-15/

    REUTERS
    16 Apr 2024
    Share Share
    UK: EPO Oppositions Newsletter - Surge In Oppositions Matches Surge In Grants
    UK: EPO Oppositions Newsletter - Surge In Oppositions Matches Surge In Grants

    26 Mar 2020

    // David Lewin MONKAQ

    https://www.mondaq.com/uk/Intellectual-Property/719168/EPO-Oppositions-Newsletter--Surge-In-Oppositions-Matches-Surge-In-Grants

    David Lewin MONKAQ
    26 Mar 2020
    Share Share
    Takeda's Shire Takeover Seen Facing EU Scrutiny of Drug Research
    Takeda's Shire Takeover Seen Facing EU Scrutiny of Drug Research

    09 May 2018

    // Aoife White BLOOMBERG

    https://www.bloomberg.com/news/articles/2018-05-08/takeda-s-shire-takeover-seen-facing-eu-scrutiny-of-drug-research

    Aoife White BLOOMBERG
    09 May 2018
    Share Share
    Dow's Merck Does An About-Face, Releases Cancer Trial Results
    Dow's Merck Does An About-Face, Releases Cancer Trial Results

    16 Jan 2018

    // INVESTORS

    https://www.investors.com/news/technology/dows-merck-does-an-about-face-releases-cancer-trial-results/

    INVESTORS
    16 Jan 2018
    Share Share
    DowDuPont completes FMC acquisition, bolsters excipient biz
    DowDuPont completes FMC acquisition, bolsters excipient biz

    06 Nov 2017

    // Dan Stanton IN PHARMATECHNOLOGIST

    https://www.in-pharmatechnologist.com/Article/2017/11/07/DowDuPont-completes-FMC-acquisition-bolsters-excipient-biz

    Dan Stanton IN PHARMATECHNOLOGIST
    06 Nov 2017
    Share Share
    Continuous Mfg : suitable excipients & more knowledge required, says Dow
    Continuous Mfg : suitable excipients & more knowledge required, says Dow

    25 Oct 2017

    // Flora Southey IN PHARMATECHNOLOGIST

    https://www.in-pharmatechnologist.com/Article/2017/10/25/Continuous-manufacturing-suitable-excipients-more-knowledge-required-says-Dow

    Flora Southey IN PHARMATECHNOLOGIST
    25 Oct 2017
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    KDMF

    read-more
    read-more

    01

    Pharma, Lab & Chemical Expo
    Not Confirmed

    01

    Polyethylene glycol 3350

    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    Union Carbide Corporation

    Registrant Name : Ace Biopharm Co., Ltd.

    Registration Date : 2021-12-02

    Registration Number : 20210517-211-J-832(1)

    Manufacturer Name : Union Carbide Corporation

    Manufacturer Address : 355 Louisiana Highway, 3142, ...

    KDMF
    ✖

    Registrant Name : Ace Biopharm Co., Ltd.

    Registration Date : 2021-12-02

    Registration Number : 20210517-211-J-832(1)

    Manufacturer Name : Union Carbide Corporation

    Manufacturer Country : U.S.A

    Manufacturer Address : 355 Louisiana Highway, 3142, Hahnville LA 70057 USA
    blank

    Excipients Web Link

    Market Place

    02

    Pharma, Lab & Chemical Expo
    Not Confirmed

    02

    Polyethylene glycol 3350

    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    Union Carbide Corporation

    Registrant Name : Taejun Pharmaceutical Co., Ltd.

    Registration Date : 2021-05-17

    Registration Number : 20210517-211-J-832

    Manufacturer Name : Union Carbide Corporation

    Manufacturer Address : 355 Louisiana Highway, 3142, ...

    KDMF
    ✖

    Registrant Name : Taejun Pharmaceutical Co., Ltd.

    Registration Date : 2021-05-17

    Registration Number : 20210517-211-J-832

    Manufacturer Name : Union Carbide Corporation

    Manufacturer Country : U.S.A

    Manufacturer Address : 355 Louisiana Highway, 3142, Hahnville LA 70057 USA
    blank

    Excipients Web Link

    Market Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients by Ingredients

    Upload your portfolio for free, ask us

    Excipients By applications

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact The Dow Chemical Company and get a quotation

    The Dow Chemical Company is a supplier offers 79 products (APIs, Excipients or Intermediates).

    Find a price of Simethicone bulk with DMF, JDMF offered by The Dow Chemical Company

    Find a price of Cholestyramine bulk with JDMF offered by The Dow Chemical Company

    Find a price of Dimethicone bulk with JDMF offered by The Dow Chemical Company

    Find a price of Amberlite Irp69 bulk with DMF offered by The Dow Chemical Company

    Find a price of Cholestyramine bulk with DMF offered by The Dow Chemical Company

    Find a price of Lauromacrogol bulk with JDMF offered by The Dow Chemical Company

    Find a price of Macrogol bulk with DMF offered by The Dow Chemical Company

    Find a price of Simethicone bulk with DMF offered by The Dow Chemical Company

    Find a price of XUS43598-SMA Ca bulk with JDMF offered by The Dow Chemical Company

    Find a price of XUS43598SF Ca bulk with JDMF offered by The Dow Chemical Company

    Find a price of XUS43598-SMA Na bulk with JDMF offered by The Dow Chemical Company

    Find a price of Amberlite Irp69 bulk offered by The Dow Chemical Company

    Find a price of Aspirin bulk offered by The Dow Chemical Company

    Find a price of Cholestyramine bulk offered by The Dow Chemical Company

    Find a price of Cyclopropane bulk offered by The Dow Chemical Company

    Find a price of Dead On Polystyrene bulk offered by The Dow Chemical Company

    Find a price of Decamethylcyclopentasiloxane bulk offered by The Dow Chemical Company

    Find a price of Dextropropoxyphene HCl bulk offered by The Dow Chemical Company

    Find a price of DPPC bulk offered by The Dow Chemical Company

    Find a price of Edetate Sodium bulk offered by The Dow Chemical Company

    Find a price of Erythromycin bulk offered by The Dow Chemical Company

    Find a price of Erythromycin Stearate bulk offered by The Dow Chemical Company

    Find a price of GUANIDINE HYDROCHLORIDE API bulk offered by The Dow Chemical Company

    Find a price of Mesalazine bulk offered by The Dow Chemical Company

    Find a price of Oxygen bulk offered by The Dow Chemical Company

    Find a price of Sevelamer Hydrochloride bulk offered by The Dow Chemical Company

    Find a price of Tetracycline bulk offered by The Dow Chemical Company

    Find a price of Theophylline bulk offered by The Dow Chemical Company

    Find a price of Vinyl Chloride bulk offered by The Dow Chemical Company

    Find a price of Xenon Radioisotopes bulk offered by The Dow Chemical Company

    Find a price of Zoalene bulk offered by The Dow Chemical Company

    Find a price of TROLENE FM MEDICATED PREMIX bulk offered by The Dow Chemical Company

    Find a price of PZ 5561.21 (DURAFILM PRODUCT) bulk offered by The Dow Chemical Company

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MIDLAND, MICHIGAN. bulk offered by The Dow Chemical Company

    Find a price of CHIMERIC (MURINE VARIABLE, HUMAN CONSTANT) MONOCLONAL ANTIBODY (CC49) TO TUMOR ASSOCIATED GLYCOPROTEIN (TAG)-72 bulk offered by The Dow Chemical Company

    Find a price of ETHOXYLATED POLYETHYLENIMINE, MONTREK 600E bulk offered by The Dow Chemical Company

    Find a price of SILASTIC 1808 ELASTOMER bulk offered by The Dow Chemical Company

    Find a price of RHOZYME 41 CONCENTRATE bulk offered by The Dow Chemical Company

    Find a price of SILICONE X-251 bulk offered by The Dow Chemical Company

    Find a price of SILASTIC 9711 MEDICAL GRADE ELASTOMER bulk offered by The Dow Chemical Company

    Find a price of BIOCRYL, BPA-1050 bulk offered by The Dow Chemical Company

    Find a price of DOW 132 (4-TERT-BUTYL-2-CHLOROPHENYLMETHYL METHY PHOSPHORAMIDATE) bulk offered by The Dow Chemical Company

    Find a price of MANUF PROCESSES OF CAP-PLATE MENICON & MAFILCON SOFT CONTACT LENS MAT. bulk offered by The Dow Chemical Company

    Find a price of VINYLITE BRAND COATED PAPER VDI 6645 WHITE 1435 bulk offered by The Dow Chemical Company

    Find a price of SILICONE RUBBER DOW CORNING SILASTIC bulk offered by The Dow Chemical Company

    Find a price of SYNTHETIC SODIUM ALUMINOSILICATE ABSORBENTS (MOLECULAR SIEVES) bulk offered by The Dow Chemical Company

    Find a price of INVESTIGATIONAL DRUG "MASTER FILE" FOR FUTURE REFS NOTICES T/B SUBMITT bulk offered by The Dow Chemical Company

    Find a price of RHOZYME J-25 CONCENTRATE bulk offered by The Dow Chemical Company

    Find a price of HYAMINE 1622 CRYSTALS (BENSETHONIUM CHLORIDE) bulk offered by The Dow Chemical Company

    Find a price of BROMINATED SALICYLANILIDE bulk offered by The Dow Chemical Company

    Find a price of MURINE MONOCLONAL ANTIBODY (COL-1) TO CEA bulk offered by The Dow Chemical Company

    Find a price of TEFLURANE bulk offered by The Dow Chemical Company

    Find a price of PERSONNEL HANDLING NEW DRUG SUBSTANCES bulk offered by The Dow Chemical Company

    Find a price of X7-2837/Q7-2837 SILICONE EMULSION AND REINFORCING AGENT bulk offered by The Dow Chemical Company

    Find a price of UNION CARBIDE'S SENTRY SIMETHICONE USP & 30% EMUL bulk offered by The Dow Chemical Company

    Find a price of POLYGLYCOL E-3350 NF bulk offered by The Dow Chemical Company

    Find a price of 20% OXYGEN, 80% ARGON AS MANUF AT TORRENCIE, CA bulk offered by The Dow Chemical Company

    Find a price of PEI 600 POLYETHYLENIMINE bulk offered by The Dow Chemical Company

    Find a price of MONOCLONAL ANTIBODY CC49 bulk offered by The Dow Chemical Company

    Find a price of HYAMINE X (QUATERNARY AMMONIUM CHLORIDE COMPOUND) bulk offered by The Dow Chemical Company

    Find a price of BIO-RELEASE SILICONE RELEASE COATING SYSTEM, HEMLOCK, MI bulk offered by The Dow Chemical Company

    Find a price of PROPYLENE GLYCOL--TRADE NAME SIRLENE (VET) bulk offered by The Dow Chemical Company

    Find a price of ETHYCELLULOSE DISPERSIONS bulk offered by The Dow Chemical Company

    Find a price of ZIRCONIA TEXTILES bulk offered by The Dow Chemical Company

    Find a price of ASPERKINASE PRODUCTION bulk offered by The Dow Chemical Company

    Find a price of POLYTHIOL RESIN bulk offered by The Dow Chemical Company

    Find a price of FACILITIES & CONTROLS (METHOXY FLURANE) bulk offered by The Dow Chemical Company

    Find a price of TERGITOL MONIONIC SURFACTANT 12-M-10 bulk offered by The Dow Chemical Company

    Find a price of FACILITIES IN SHIZOUKA, JAPAN bulk offered by The Dow Chemical Company

    Find a price of POLYMER JR & LR RESINS bulk offered by The Dow Chemical Company

    Find a price of BIOCRYL, BPA-1000 bulk offered by The Dow Chemical Company

    Find a price of UCC MASTER MILKER SYSTEM FOR TC-99 EXTRACTION FROM MO-99 bulk offered by The Dow Chemical Company

    Find a price of VERSENE CA. CALCIUM CHELATING AGENT bulk offered by The Dow Chemical Company

    Find a price of HYDROXYETHYL METHACRYLATE 94% bulk offered by The Dow Chemical Company

    Find a price of DISIDIUM DIHYDROGEN VERSENATE, A.R. bulk offered by The Dow Chemical Company

    Find a price of UNS-TETRAFLUOROETHANE bulk offered by The Dow Chemical Company

    Find a price of BIOCRYL BPA-5050PMN bulk offered by The Dow Chemical Company

    Find a price of TERGITOL ANIONIC SURFACTANT 4 bulk offered by The Dow Chemical Company

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN PITTSBURG, CAL. bulk offered by The Dow Chemical Company

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search